Panacea Biotec launches hexavalent combination vaccine ‘EasySix’

29 Mar 2017 Evaluate

Panacea Biotec has launched world's first fully liquid whole cell Pertussis (wP) based hexavalent combination vaccine, EasySix, a vaccine Researched, Developed and Manufactured by Panacea Biotec in India. EasySix is indicated for primary immunization to protect newborn babies against six common preventable diseases that is Diphtheria, Tetanus, Whooping Cough, Meningitis (due to H. Influenza type b), Hepatitis B and Polio.

EasySix is a fully liquid ready-to-use hexavalent vaccine made using high quality antigens complying to WHO's cGMP requirements. The fully liquid 6-in-1 combination vaccine EasySix requires no reconstitution, therefore saves time, is convenient and minimizes chances of error.

Panacea Biotec is one of India’s leading research based Biopharmaceutical Company with established research, manufacturing and marketing capabilities. The company has product portfolio that’s caters therapeutics areas like pain management, diabetes and cardiovascular management, renal disease management, osteoporosis management, anti-tubercular, gastro-intestinal.

Panacea Biotec Share Price

120.40 -3.05 (-2.47%)
28-Mar-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1620.50
Dr. Reddys Lab 6171.85
Cipla 1494.65
Zydus Lifesciences 1013.75
Lupin 1617.85
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.